Mixed Epithelial Carcinoma Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
CONCLUSIONS: HER2 GPA can be used to accurately determine HER2 status in endometrial cancers and is a highly valuable tool for identifying HER2 heterogeneity.PMID:36857635 | DOI:10.1093/ajcp/aqac179 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - March 1, 2023 Category: Pathology Authors: Saba Shafi Hiroaki Nitta Manan Shah Bindu Challa Anil V Parwani Zaibo Li Source Type: research
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
CONCLUSIONS: HER2 GPA can be used to accurately determine HER2 status in endometrial cancers and is a highly valuable tool for identifying HER2 heterogeneity.PMID:36857635 | DOI:10.1093/ajcp/aqac179 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 1, 2023 Category: Cancer & Oncology Authors: Saba Shafi Hiroaki Nitta Manan Shah Bindu Challa Anil V Parwani Zaibo Li Source Type: research
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
CONCLUSIONS: HER2 GPA can be used to accurately determine HER2 status in endometrial cancers and is a highly valuable tool for identifying HER2 heterogeneity.PMID:36857635 | DOI:10.1093/ajcp/aqac179 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 1, 2023 Category: Cancer & Oncology Authors: Saba Shafi Hiroaki Nitta Manan Shah Bindu Challa Anil V Parwani Zaibo Li Source Type: research
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
CONCLUSIONS: HER2 GPA can be used to accurately determine HER2 status in endometrial cancers and is a highly valuable tool for identifying HER2 heterogeneity.PMID:36857635 | DOI:10.1093/ajcp/aqac179 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - March 1, 2023 Category: Pathology Authors: Saba Shafi Hiroaki Nitta Manan Shah Bindu Challa Anil V Parwani Zaibo Li Source Type: research
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers
CONCLUSIONS: HER2 GPA can be used to accurately determine HER2 status in endometrial cancers and is a highly valuable tool for identifying HER2 heterogeneity.PMID:36857635 | DOI:10.1093/ajcp/aqac179 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - March 1, 2023 Category: Pathology Authors: Saba Shafi Hiroaki Nitta Manan Shah Bindu Challa Anil V Parwani Zaibo Li Source Type: research
Mixed epithelial and stromal tumor of the kidney: A case report
Oncol Lett. 2022 Nov 23;25(1):25. doi: 10.3892/ol.2022.13611. eCollection 2023 Jan.ABSTRACTMixed epithelial and stromal tumor (MEST) is a rare neoplasm of the kidney, affecting mostly women at menopausal age. While few cases of malignant transformation have been described in the literature, MEST is usually considered a benign tumor with minimal risk of local recurrence or distance metastases. The current study presents a case of a 18-year old male patient with a cystic tumor of the left kidney incidentally diagnosed on magnetic resonance imaging of the heart performed for other reasons. The patient underwent a partial neph...
Source: Oncology Letters - December 8, 2022 Category: Cancer & Oncology Authors: Piotr Kalinowski Tomasz Kalinowski Jakub Kucharz Hubert Kamecki Bernard Adamowicz Krzysztof Sikora Joanna Podg órska Tomasz Demkow Source Type: research
Mixed epithelial and stromal tumor of the kidney: A case report
Oncol Lett. 2022 Nov 23;25(1):25. doi: 10.3892/ol.2022.13611. eCollection 2023 Jan.NO ABSTRACTPMID:36478902 | PMC:PMC9713829 | DOI:10.3892/ol.2022.13611 (Source: Oncology Letters)
Source: Oncology Letters - December 8, 2022 Category: Cancer & Oncology Authors: Piotr Kalinowski Tomasz Kalinowski Jakub Kucharz Hubert Kamecki Bernard Adamowicz Krzysztof Sikora Joanna Podg órska Tomasz Demkow Source Type: research
